8. Sponsored Research and Clinical Trial Agreements

Aevitas

Duke SRA

On September 1, 2019, Aevitas entered into a Sponsored Research Arrangement ("SRA") with Duke University School of Medicine ("Duke") for the purpose of conducting a study to identify a dose range for AAV8 vectors in Dry Age-related Macular Degeneration ("Dry AMD"). The cost of the SRA is approximately $0.1 million. The study is expected to be completed in four months. For the three and nine months ended September 30, 2019, Aevitas recorded approximately $17,000 in research and development expense on the condensed consolidated statement of operations. No expense related to this SRA was recorded in 2018.

UMass/UPenn SRA

In 2018, Aevitas entered into a Sponsored Research Agreement (“SRA”) with the University of Massachusetts (“UMass SRA”) for certain continued research and development activities related to the development of adeno-associated virus (“AAV”) gene therapies in complement-mediated diseases and with the Trustees of the University of Pennsylvania (“UPenn SRA”) for certain continued research and development activities related to the development of AAV gene therapies in complement-mediated diseases. For the three and nine months ended September 30, 2019 and 2018, Aevitas recorded the following expense in research and development for sponsored research and clinical trial agreements:

 

 

Cellvation

For the three and nine months ended September 30, 2019 and 2018, respectively, Cellvation recorded expense of nil million and $0.1 million and $0.1 million and $0.2 million, respectively in connection with its sponsored research arrangement with the University of Texas. The expense was recorded in research and development expense in the Condensed Consolidated Statements of Operations.

Mustang

For the three and nine months ended September 30, 2019 and 2018, Mustang recorded the following expense in research and development for sponsored research and clinical trial agreements: